Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study

European Journal of Haematology

Volumn 87, Issue 4, 2011, Pages 349-354

  Taher, Ali ^a   Elalfy, Mohsen S ^b   Al Zir, Kusai ^c   Daar, Shahina ^d   Al Jefri, Abdullah ^e   Habr, Dany ^f   Kriemler Krahn, Ulrike ^f   Roubert, Bernard ^f   El Beshlawy, Amal ^g  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c National Thalassemia Center   (Syrian Arab Republic)

^d SULTAN QABOOS UNIVERSITY   (Oman)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f NOVARTIS PHARMA AG   (Switzerland)

^g CAIRO UNIVERSITY   (Egypt)

Author keywords

thalassaemia; Deferasirox; Efficacy; Iron chelation therapy; Iron overload

Indexed keywords

DEFERASIROX; DEFERIPRONE; IRON;

ABNORMAL LABORATORY RESULT; ADOLESCENT; ARTICLE; BETA THALASSEMIA; CHILD; CREATININE BLOOD LEVEL; DEATH; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON INTAKE; IRON OVERLOAD; LIVER IRON CONCENTRATION; LIVER LEVEL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OBSTRUCTIVE JAUNDICE; OPEN STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; ULCER PERFORATION;

ADOLESCENT; BENZOIC ACIDS; BETA-THALASSEMIA; BODY BURDEN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MALE; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 80053284827     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01661.x     Document Type: Article

References (6)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
2. Taher A, El-Beshlawy A, Elalfy MS, Al ZK, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al JA. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458-65.
3. Taher A, Elalfy MS, Al ZK, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, El-Ali A, Roubert B, El-Beshlawy A. Importance of optimal dosing 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol (in press).
4. Pfisterer ME, Battler A, Zaret BL. Range of normal values for left and right ventricular ejection fraction at rest and during exercise assessed by radionuclide angiocardiography. Eur Heart J 1985;6:647-55.
5. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
6. Porter JB, Elalfy M, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Taher A, Habr D, Roubert B, El-Beshlawy A. Efficacy and safety of deferasirox in patients with baseline liver iron concentration (LIC) <7 or >=7mg Fe/g dw: results of EPIC liver magnetic resonance imaging (MRI) substudy. Haematologica 2010;95(Suppl 2):abst 1823.